Find a Tender
planning
Official procurement procedure
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
Pharmaceutical products
Various medicinal products
UK
Published value
£1,516,353,164
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025". Published status: planning. Published value: £1,516,353,164. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | NHS England | Scope & Categories | Not published | Submission Window | planning No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | £1,516,353,164 |
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
22.8Bids / Report
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable valuePayment Terms
Check noticePublished terms
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
| Supplier Name | Historic Awards | Attributable GBP Value |
|---|---|---|
| Anna Freud | 1 win | £5,862,540 |
| Anglia Ruskin University | 1 win | £4,809,159 |
| NHS Shared Business Services Limited | 1 win | £4,393,727 |
| Pearson Professional Assessments Limited | 1 win | £4,374,320 |
| Timewise Foundation CIC | 1 win | £166,667 |
Procedure terms
Contracting AuthorityNHS England | Procedure methodNot published | Procurement categoryNot published |
Statusplanning | Framework / DPSFramework | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published21 Mar 2025, 08:15 GMT | Last source update21 Mar 2025, 08:15 GMT | Recurring procurementNot published |
ClassificationPharmaceutical products, Various medicinal products | ||
Delivery area UK | ||
OCIDocds-h6vhtk-04f706 | ||
What is being bought
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
What changed
From the official release history
- Published value updated to £1,516,353,164
21 Mar 2025, 08:15 GMT - Status changed to planning
21 Mar 2025, 08:15 GMT - Official notice release published
21 Mar 2025, 08:15 GMT - Buyer information updated
21 Mar 2025, 08:15 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedplanningPublished valueNot publishedThe source published no individual title or description for this lot.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Pipeline notice
21 Mar 2025, 08:15 GMT - Procedure published
21 Mar 2025, 08:15 GMT - engagement
11 Apr 2025, 23:59 BST · scheduledNHS England is pleased to invite suppliers to a virtual 1:1 preliminary market engagement meeting in relation to the upcoming re-tender of the Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines Framework. The purpose of the sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, clinical aspects and KPI's. Please contact b.kullootee@nhs.net or michelle.clarke6@nhs.net to register your interest. There will also be a 7 day window for queries to be raised in writing after all sessions have concluded.
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
NHS England
Contracting authority GB-PPON-PDPT-3135-BWWYDocuments (1)
Official links; attachments are not copied
- 21 Mar 2025, 08:15 GMT
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleNot published |